In a major advance for infectious disease treatment, researchers from Monash University and The Alfred have developed a bespoke phage therapy product that uses bacterial viruses, known as “bacteriophages,” to combat a highly problematic, antimicrobial-resistant bacteria.
Microbiologists develop bespoke phage therapy to combat antimicrobial resistance
